Aptar Pharma QuickStart, an injectable device development kit, to launch at CPhI Worldwide
26 October 2018
Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, 9 October.
Aptar Pharma QuickStart is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, QuickStart provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilisation and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart is available to cater to different sizes and configurations of vials, stoppers and caps.
Aptar Pharma’s proven expertise in device development and formulation helps ensure that QuickStart’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.
CPhI Worldwide, which takes place 9-11 October, 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals, which provides a prime opportunity to demonstrate the value of Aptar Pharma QuickStart to prospective partners.
Adam Shain, Aptar Pharma’s director, Global Business Development – Injectables, comments, “We are excited to be launching Aptar Pharma QuickStart at CPhI Worldwide, a solution which we are confident will accelerate pharma companies’ bench-to-market. QuickStart is all about convenience and speed by enabling R&D labs to maintain a positive development experience from project outset, including the ability to control the component configuration in terms of coating, volume and size, and that the integrity of the container closure for delivery mechanisms can be maintained.”
Luce Sohier, SCHOTT, Business Development adds, “We appreciate that the SCHOTT Topline Vials were choosen to be part of Aptar Pharma QuickStart. We share the vision that enabling our customers to expedite their reseach is critical. We also see as a real asset that we are providing our customers with the neccessary quality documentation for regulatory
filing.”
Stefan Greife, sales director of EMA Pharmaceuticals concludes, “We are very proud to be part of this collaboration for the launch of QuickStart, providing our customers with a robust, easy-to-use solution.”
Visit Aptar Pharma at CPhI at stand 4D10, Hall 4 to find out more about Aptar Pharma QuickStart and Aptar Pharma’s broad range of innovative drug delivery systems.
